Cipla has been given a new recommendation by brokerage Axis Securities, indicating a potential upside of 15.24%. The target price is Rs 1735.0, while the stock was priced at Rs 1489.0 at the time of ...

Analysts have given recommendations for companies including Devyani International Ltd., Cipla Ltd., Oberoi Realty Ltd., Bank Of Baroda, and more. As per the stock calls shared with NDTV Profit, some ...

Therefore, when the medication is gone from the inhaler, it is possible to continue to inhale only propellant and no medicine. This can be dangerous, especially in the case of rescue inhalers that are ...

One of the primary differences between asthma inhalers is whether they are meant for quick relief of an asthma attack (referred to as a rescue inhaler) or are used on a daily basis to help better ...

Cipla's stock is trading at Rs 1470.80, down by 0.34% today. The 5-year returns highlight a strong performance with a total of 216.19%. The last trading session saw Cipla close at Rs 1475.75, with a ...

India’s rising players in the GLP-1 market Indian pharmaceutical giants like Sun Pharma, Cipla, Dr. Reddy’s, Natco Pharma, and Lupin are in a fierce race to bring obesity drugs to the Indian ...

Pharma major Cipla Ltd on Friday (December 20, 2024) said a fine of over ₹1 crore has been imposed on the company by GST authority for alleged inadmissible credit claim. The company has received ...

Hannah Garden-Monheit, the director of the FTC's Office of Policy Planning, said in a statement that the decision was "important not only for lowering asthma inhaler costs, it also sets the stage ...

Pharma major Cipla Ltd on Friday said a fine of over Rs 1 crore has been imposed on the company by GST authorities for alleged inadmissible credit claim. The company has received an order dated ...

NEW DELHI, Dec 20: Pharma major Cipla Ltd on Friday said a fine of over Rs 1 crore has been imposed on the company by GST authority for alleged inadmissible credit claim. The company has received an ...

A device costing just pennies, based on an idea by a University of Manchester Professor to help his son use an inhaler, could be a gamechanger for asthma patients. The impressive results are from ...

Cipla shares gained over 2 percent on December 17 after Kotak Institutional Equities upgraded the stock to a 'buy' from its previous 'add' rating. The upgrade was driven by factors such as ...